JP2011508605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508605A5 JP2011508605A5 JP2010541566A JP2010541566A JP2011508605A5 JP 2011508605 A5 JP2011508605 A5 JP 2011508605A5 JP 2010541566 A JP2010541566 A JP 2010541566A JP 2010541566 A JP2010541566 A JP 2010541566A JP 2011508605 A5 JP2011508605 A5 JP 2011508605A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- composition
- osteopontin
- wound
- connexin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 123
- 108091033319 polynucleotide Proteins 0.000 claims description 119
- 239000002157 polynucleotide Substances 0.000 claims description 119
- 102000040430 polynucleotide Human genes 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 70
- 206010052428 Wound Diseases 0.000 claims description 56
- 208000027418 Wounds and injury Diseases 0.000 claims description 56
- 238000009472 formulation Methods 0.000 claims description 56
- 102000004264 Osteopontin Human genes 0.000 claims description 43
- 108010081689 Osteopontin Proteins 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 41
- 230000000692 anti-sense effect Effects 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000003357 wound healing promoting agent Substances 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000001045 Connexin 43 Human genes 0.000 claims description 14
- 108010069241 Connexin 43 Proteins 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 14
- 239000000499 gel Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000000816 peptidomimetic Substances 0.000 claims description 10
- 230000029663 wound healing Effects 0.000 claims description 10
- 102000010970 Connexin Human genes 0.000 claims description 8
- 108050001175 Connexin Proteins 0.000 claims description 8
- 108091030071 RNAI Proteins 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 6
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 claims description 6
- 101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims description 6
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 210000003976 gap junction Anatomy 0.000 claims description 6
- 102000051312 human SPP1 Human genes 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 230000036573 scar formation Effects 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 5
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 5
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000003828 downregulation Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 239000002981 blocking agent Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091027075 5S-rRNA precursor Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 150000004713 phosphodiesters Chemical class 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- 230000037314 wound repair Effects 0.000 claims description 2
- 125000002796 nucleotidyl group Chemical group 0.000 claims 2
- 241000009328 Perro Species 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1039108P | 2008-01-07 | 2008-01-07 | |
| PCT/US2009/000129 WO2009097077A2 (en) | 2008-01-07 | 2009-01-07 | Wound healing compositions and treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022668A Division JP2015096078A (ja) | 2008-01-07 | 2015-02-06 | 創傷治癒組成物および治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011508605A JP2011508605A (ja) | 2011-03-17 |
| JP2011508605A5 true JP2011508605A5 (https=) | 2013-02-28 |
Family
ID=40674156
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541566A Withdrawn JP2011508605A (ja) | 2008-01-07 | 2009-01-07 | 創傷治癒組成物および治療 |
| JP2015022668A Pending JP2015096078A (ja) | 2008-01-07 | 2015-02-06 | 創傷治癒組成物および治療 |
| JP2017110156A Pending JP2017148075A (ja) | 2008-01-07 | 2017-06-02 | 創傷治癒組成物および治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015022668A Pending JP2015096078A (ja) | 2008-01-07 | 2015-02-06 | 創傷治癒組成物および治療 |
| JP2017110156A Pending JP2017148075A (ja) | 2008-01-07 | 2017-06-02 | 創傷治癒組成物および治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110038920A1 (https=) |
| EP (1) | EP2240583A2 (https=) |
| JP (3) | JP2011508605A (https=) |
| CA (1) | CA2711635A1 (https=) |
| WO (1) | WO2009097077A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073629B1 (ko) | 2005-02-03 | 2020-02-05 | 코다 테라퓨틱스 (엔지) 리미티드 | 항-코넥신 화합물 및 그의 용도 |
| EP2245158A2 (en) * | 2007-12-11 | 2010-11-03 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| US8975237B2 (en) | 2007-12-21 | 2015-03-10 | Coda Therapeutics, Inc. | Treatment of fibrotic conditions |
| US9135693B2 (en) * | 2010-05-18 | 2015-09-15 | Skin Of Mine Dot Com, Llc | Image calibration and analysis |
| EP3263121B1 (en) * | 2010-12-21 | 2019-02-27 | Leidos, Inc. | Methods and compositions for wound treatment |
| WO2012110457A2 (en) | 2011-02-14 | 2012-08-23 | Santaris Pharma A/S | Compounds for the modulation of osteopontin expression |
| DE102011109868A1 (de) * | 2011-08-10 | 2013-02-14 | STERNA BIOLOGICALS GmbH & Co. KG. | Multiple Emulsion |
| DK2819682T3 (en) * | 2012-03-01 | 2017-08-21 | Firststring Res Inc | TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES |
| US20140274872A1 (en) * | 2013-03-15 | 2014-09-18 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
| WO2013148736A1 (en) * | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
| GB201207056D0 (en) * | 2012-04-23 | 2012-06-06 | Ucl Business Plc | Wound treatment |
| US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| WO2015017034A1 (en) * | 2013-08-02 | 2015-02-05 | Gourdie Robert G | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
| US20150352064A1 (en) * | 2014-06-10 | 2015-12-10 | Kuwait University | Method of treating delayed healing of a wound associated with diabetes |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| WO2016175548A1 (ko) * | 2015-04-27 | 2016-11-03 | 주식회사 파마리서치프로덕트 | 생체적합성 천연고분자 및 dna 단편 혼합물을 함유하는 유착방지제 및 이의 제조 방법 |
| WO2018039302A1 (en) * | 2016-08-23 | 2018-03-01 | The Cleveland Clinic Foundation | Cancer treatment using cx26 blocking peptides |
| CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
| WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
| MX2023004631A (es) | 2020-10-22 | 2023-07-20 | Xequel Bio Inc | Formulaciones peptidicas y usos oftalmicos de las mismas. |
| CN115466309A (zh) * | 2021-06-10 | 2022-12-13 | 首都医科大学 | 抗粘附和迁移的18β-甘草次酸-HGE,其合成,抗癌转移活性和应用 |
| CN115707772B (zh) * | 2021-08-18 | 2025-08-08 | 澳门大学 | 一种诱导剂、巨噬细胞及其应用 |
| CN114099767A (zh) * | 2021-10-12 | 2022-03-01 | 湖北兵兵药业(集团)有限公司 | 一种具有抗菌消炎功能的液体伤口敷料及其制备方法 |
| CN121046387B (zh) * | 2025-11-03 | 2026-02-06 | 谷雨生物科技集团股份有限公司 | 一种具有抗皮肤细胞衰老和修护功效的siRNA及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| JPH0539594Y2 (https=) * | 1988-08-05 | 1993-10-07 | ||
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US6752987B1 (en) * | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| AU9016898A (en) * | 1997-08-07 | 1999-03-01 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Methods and compositions for treatment of restenosis |
| WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2314321B1 (en) * | 1999-01-27 | 2014-06-04 | Coda Therapeutics, Inc. | Formulations comprising antisense nucleotides to connexins |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CA2425662A1 (en) * | 2000-10-18 | 2002-04-25 | Children's Medical Center Corporation | Osteopontin-coated surfaces and methods of use |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| JP2005509621A (ja) * | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにｅｄｈｆ |
| CN1638790A (zh) * | 2002-01-29 | 2005-07-13 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
| WO2003096981A2 (en) * | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1514929A1 (en) * | 2003-09-12 | 2005-03-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| KR101350837B1 (ko) * | 2003-12-03 | 2014-01-14 | 코다 테라퓨틱스, 인크. | 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법 |
| KR20080088600A (ko) * | 2005-12-16 | 2008-10-02 | 아를라 푸즈 에이엠비에이 | 상처 치유 방법의 개선을 위한 소 오스테오폰틴 제제 |
| AU2008223817A1 (en) * | 2007-03-02 | 2008-09-12 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
| EP2155234A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for chronic dermal ulcers |
-
2009
- 2009-01-07 CA CA2711635A patent/CA2711635A1/en not_active Abandoned
- 2009-01-07 EP EP09705465A patent/EP2240583A2/en not_active Withdrawn
- 2009-01-07 JP JP2010541566A patent/JP2011508605A/ja not_active Withdrawn
- 2009-01-07 US US12/812,017 patent/US20110038920A1/en not_active Abandoned
- 2009-01-07 WO PCT/US2009/000129 patent/WO2009097077A2/en not_active Ceased
-
2015
- 2015-02-06 JP JP2015022668A patent/JP2015096078A/ja active Pending
-
2017
- 2017-06-02 JP JP2017110156A patent/JP2017148075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508605A5 (https=) | ||
| JP2011506447A5 (https=) | ||
| RU2009122370A (ru) | Улучшенные способы и композиции для заживления ран | |
| JP2011507860A5 (https=) | ||
| DK2101791T3 (en) | ANTICONNEXIN POLYNUCLEOTIDES AS COMPOSITIONS AGAINST DEGRADED HEALTH | |
| JP4994533B2 (ja) | コネキシンに対するアンチセンスヌクレオチドを含む配合物 | |
| US20110130710A1 (en) | Treatment of abnormal or excessive scars | |
| US9738892B2 (en) | Treatment of fibrotic conditions | |
| JP2011507858A5 (https=) | ||
| JP2011507855A5 (https=) | ||
| JP2011507861A5 (https=) | ||
| JP2011256204A5 (https=) | ||
| JP2014144976A (ja) | 損傷した創傷治癒組成物および治療 | |
| JP2011508605A (ja) | 創傷治癒組成物および治療 | |
| JP2015057430A (ja) | 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用 | |
| JP2015083606A (ja) | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 | |
| US20110144182A1 (en) | Treatment of surgical adhesions | |
| JP2024045151A (ja) | Ｃｐｇアンフィフィル及びその使用 | |
| CA2389036A1 (en) | Antisense modulation of integrin-linked kinase expression | |
| JP2004517630A5 (https=) | ||
| CA3249549A1 (en) | METHODS OF TREATING IMMUNE DYSFUNCTION IN LIVER CANCER WITH TOL-TYPE RECEPTOR AGONISTS | |
| Chung et al. | [34] In vitro and in vivo modulation of transforming growth factor β1 gene expression by antisense oligomer |